Oxford Biomedica (OXB) RNS Announcements

Add to Alert list
Date Time Source Announcement
13 Apr 2022 07:00 AM
RNS
Board Appointment
04 Apr 2022 11:34 AM
RNS
Notice of Preliminary Results
01 Apr 2022 06:30 PM
RNS
Holding(s) in Company
01 Apr 2022 10:33 AM
RNS
Block listing Application
01 Apr 2022 09:34 AM
RNS
Total Voting Rights
31 Mar 2022 06:07 PM
RNS
Holding(s) in Company
30 Mar 2022 01:00 PM
RNS
Holding(s) in Company
25 Mar 2022 05:15 PM
RNS
Holding(s) in Company
21 Mar 2022 10:44 AM
RNS
Long Term Incentive Plan Option Grant
15 Mar 2022 11:25 AM
RNS
Holding(s) in Company
15 Mar 2022 09:39 AM
RNS
Holding(s) in Company
11 Mar 2022 04:51 PM
RNS
Holding(s) in Company
11 Mar 2022 12:00 PM
Oxford Biomedica broadens its viral vector capa...
11 Mar 2022 09:01 AM
RNS
Admission of Conditional Placing Shares
10 Mar 2022 05:32 PM
RNS
Completion of Transaction
09 Mar 2022 11:42 AM
RNS
Director Declaration
08 Mar 2022 03:54 PM
RNS
Result of General Meeting
01 Mar 2022 09:52 AM
RNS
Total Voting Rights
16 Feb 2022 11:41 AM
RNS
Publication of Circular & Notice of GM
04 Feb 2022 08:22 AM
RNS
Admission of Firm Placing Shares
01 Feb 2022 09:06 AM
RNS
Total Voting Rights
01 Feb 2022 07:00 AM
RNS
Update to agreement with Sio Gene Therapies
31 Jan 2022 09:13 PM
Oxford Biomedica announces update to agreement ...
31 Jan 2022 11:21 AM
RNS
Market Share Purchase
28 Jan 2022 05:59 PM
RNS
Result of Placing and PrimaryBid offer
28 Jan 2022 02:04 PM
RNS
Holdings in Company
28 Jan 2022 07:39 AM
Oxford Biomedica broadens leading viral vector ...
28 Jan 2022 07:38 AM
RNS
Retail offer by PrimaryBid
28 Jan 2022 07:24 AM
RNS
US Agreement and Proposed Placing of Shares
17 Jan 2022 07:00 AM
RNS
John Dawson to retire from Oxford Biomedica
05 Jan 2022 07:00 AM
RNS
Oxford Biomedica Agreement with Cabaletta Bio
04 Jan 2022 11:07 AM
RNS
Block listing Return
04 Jan 2022 10:32 AM
RNS
Total Voting Rights
04 Jan 2022 07:00 AM
RNS
John Dawson awarded CBE in New Year Honours List
14 Dec 2021 07:00 AM
RNS
Board Appointment
13 Dec 2021 07:00 AM
RNS
Oxford Biomedica Signs Agreement with Arcellx
13 Dec 2021 07:00 AM
RNS
Oxford Biomedica Updates Lentiviral Agreement
01 Dec 2021 09:49 AM
RNS
Total Voting Rights
01 Nov 2021 10:08 AM
RNS
Long Term Incentive Plan Option Grant
01 Nov 2021 10:02 AM
RNS
Total Voting Rights
19 Oct 2021 07:00 AM
RNS
Boehringer Ingelheim Exercises Option
01 Oct 2021 09:51 AM
RNS
Total Voting Rights
29 Sep 2021 05:54 PM
RNS
Holding(s) in Company
29 Sep 2021 05:36 PM
RNS
Directors Dealings / Market Share Purchases
28 Sep 2021 04:48 PM
RNS
Holding(s) in Company
28 Sep 2021 10:01 AM
RNS
Total Voting Rights
22 Sep 2021 07:38 AM
RNS
Strategic investment by Serum Life Sciences
22 Sep 2021 07:00 AM
RNS
Interim Results
01 Sep 2021 10:48 AM
RNS
Total Voting Rights
01 Sep 2021 07:00 AM
RNS
Notice of Interim Results

Oxford Biomedica is a company that specialises in cell and gene therapy, and is a leader in the development of gene-based medicines. They work with pharmaceutical and biotechnology companies to develop and manufacture viral vectors, including lentivirus, adeno-associated virus, and adenoviral vectors.

Headquartered in Oxford, Oxford Biomedica has manufacturing facilities in Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US.

Oxford Biomedica share price listed in London under the ticker OXB at 2,570p.

UK 100

Latest directors dealings